Workflow
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
Globenewswire·2025-10-01 12:41
  • Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents 1.5billionU.S.totaladdressablemarket−GAITHERSBURG,Md.,Oct.01,2025(GLOBENEWSWIRE)−−ElutiaInc.(Nasdaq:ELUT)(“Elutia”orthe“Company”),apioneerindrug−elutingbiomatrixtechnologies,todayannouncedtheclosingofthesaleofitsBioEnvelopebusiness,includingtheEluPro™andCanGaroo®bioenvelopes,toBostonScientificCorporation(NYSE:BSX)for1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: BSX) for 88 ...